Voya Investment Management LLC Trims Stock Holdings in Intellia Therapeutics, Inc. $NTLA

Voya Investment Management LLC lowered its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 42.5% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 153,456 shares of the company’s stock after selling 113,605 shares during the period. Voya Investment Management LLC owned 0.14% of Intellia Therapeutics worth $2,650,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NTLA. Marex Group plc acquired a new stake in shares of Intellia Therapeutics during the 2nd quarter worth about $5,849,000. JPMorgan Chase & Co. lifted its stake in shares of Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase & Co. now owns 940,483 shares of the company’s stock valued at $8,822,000 after buying an additional 396,858 shares during the period. Schroder Investment Management Group lifted its stake in shares of Intellia Therapeutics by 1,593.4% during the second quarter. Schroder Investment Management Group now owns 406,425 shares of the company’s stock valued at $3,812,000 after buying an additional 382,425 shares during the period. Armistice Capital LLC acquired a new stake in Intellia Therapeutics during the first quarter worth approximately $2,588,000. Finally, Vestmark Advisory Solutions Inc. grew its stake in Intellia Therapeutics by 104.7% in the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company’s stock worth $5,988,000 after acquiring an additional 326,460 shares during the period. Institutional investors and hedge funds own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Bank of America lowered their price objective on Intellia Therapeutics from $36.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Citigroup restated a “market outperform” rating on shares of Intellia Therapeutics in a report on Tuesday, October 28th. JPMorgan Chase & Co. reiterated an “underweight” rating and set a $5.00 price objective (down from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. JMP Securities lowered their target price on shares of Intellia Therapeutics from $33.00 to $29.00 and set a “market outperform” rating for the company in a report on Tuesday, October 28th. Finally, Sanford C. Bernstein set a $14.50 price target on shares of Intellia Therapeutics in a research report on Tuesday, October 28th. Eleven equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $18.43.

Insider Buying and Selling at Intellia Therapeutics

In related news, CAO Michael P. Dube sold 1,871 shares of the company’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at approximately $960,523.08. This represents a 3.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 3.10% of the company’s stock.

Intellia Therapeutics Stock Performance

NTLA opened at $9.44 on Friday. Intellia Therapeutics, Inc. has a 1 year low of $5.90 and a 1 year high of $28.25. The firm has a 50 day moving average price of $11.48 and a 200 day moving average price of $12.66. The company has a market cap of $1.09 billion, a PE ratio of -2.21 and a beta of 2.13.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative net margin of 774.94% and a negative return on equity of 57.01%. The firm had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. During the same period in the previous year, the company posted ($1.34) earnings per share. Intellia Therapeutics’s revenue was up 51.6% compared to the same quarter last year. On average, sell-side analysts predict that Intellia Therapeutics, Inc. will post -5.07 earnings per share for the current year.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical?stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease?causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.